Effects of endothelial nitric oxide synthase gene on end stage renal disease progression in autosomal dominant polycystic kidney disease

Nephrology

Volumn 19, Issue 10, 2014, Pages 630-637

  Xue, Cheng ^a,b   Zhou, Chen Chen ^b   Sun, Li Jun ^b   He, Liang Liang ^b   Xu, Cheng Gang ^b   Dai, Bing ^b   Mei, Chang Lin ^b  

^a The 302th Hospital of Chinese People s Liberation Army   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Autosomal dominant polycystic kidney disease; Endothelial nitric oxide synthase; Meta analysis; Polymorphism

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; NOS3 PROTEIN, HUMAN;

ALLELE; ARTICLE; CARDIOVASCULAR RISK; DISEASE COURSE; DNA POLYMORPHISM; END STAGE RENAL DISEASE; GENETIC ASSOCIATION; GENETIC MODEL; GENOTYPE; HETEROZYGOTE; HUMAN; HYPERTENSION; KIDNEY POLYCYSTIC DISEASE; ONSET AGE; PHENOTYPE; SYSTEMATIC REVIEW; ADULT; AGE; CAUCASIAN; CHRONIC KIDNEY FAILURE; ENZYMOLOGY; ETHNOLOGY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HOMOZYGOTE; MALE; META ANALYSIS; MIDDLE AGED; RISK; RISK FACTOR; SEX DIFFERENCE;

ADULT; AGE FACTORS; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; ODDS RATIO; PHENOTYPE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; POLYMORPHISM, GENETIC; RISK FACTORS; SEX FACTORS;

EID: 84907851572     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12310     Document Type: Article

References (27)

1. Wuthrich RP, Mei C. Pharmacological management of polycystic kidney disease. Expert Opin. Pharmacother. 2014; 15: 1085-95.
2. Mao Z, Xie G, Ong AC. Metabolic abnormalities in autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 2014; doi:10.1093/ndt/gfu044 [Epub ahead of print].
3. Pereira TV, Nunes AC, Rudnicki M et al. Influence of ACE I/D gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease: A meta-analysis. Nephrol. Dial. Transplant. 2006; 21: 3155-63.
4. Ta MH, Harris DC, Rangan GK. Role of interstitial inflammation in the pathogenesis of polycystic kidney disease. Nephrology (Carlton) 2013; 18: 317-30.
5. Dasar N, Ghaderian SM, Azargashb E. Human evaluation of the Glu298Asp polymorphism in NOS3 gene and its relationship with onset age of ESRD in Iranian patients suffering from ADPKD. Int. J. Mol. Cell. Med. 2012; 1: 105-12.
6. Walker D, Consugar M, Slezak J et al. The ENOS polymorphism is not associated with severity of renal disease in polycystic kidney disease 1. Am. J. Kidney Dis. 2003; 41: 90-94.
7. Yun Z, Yu-Ping Y, Zong-Wu T et al. Association of endothelial nitric oxide synthase gene polymorphisms with end-stage renal disease: A systematic review and meta-analysis. Ren. Fail. 2014; 36: 987-993.
8. Reiterova J, Merta M, Tesar V et al. Endothelial nitric oxide synthase affects the progression of autosomal dominant polycystic kidney disease. Kidney Blood Press. Res. 2002; 25: 87-90.
9. Merta M, Reiterova J, Tesar V et al. Influence of the endothelial nitric oxide synthase polymorphism on the progression of autosomal dominant polycystic kidney disease and IgA nephropathy. Ren. Fail. 2002; 24: 585-93.
10. Persu A, Stoenoiu MS, Messiaen T et al. Modifier effect of ENOS in autosomal dominant polycystic kidney disease. Hum. Mol. Genet. 2002; 11: 229-41.
11. Azurmendi P, Fraga A, Muchnik C et al. [Progression of autosomic dominant polycystic kidney disease. Influence of endothelial NO synthase (ecNOS) and renin angiotensin system gene polymorphisms]. Medicina 2004; 64: 139-42.
12. Lamnissou K, Zirogiannis P, Trygonis S et al. Evidence for association of endothelial cell nitric oxide synthase gene polymorphism with earlier progression to end-stage renal disease in a cohort of Hellens from Greece and Cyprus. Genet. Test. 2004; 8: 319-24.
13. Reiterova J, Miroslav M, Stekrova J et al. The influence of G-protein beta3-subunit gene and endothelial nitric oxide synthase gene in exon 7 polymorphisms on progression of autosomal dominant polycystic kidney disease. Ren. Fail. 2004; 26: 119-25.
14. Stefanakis N, Ziroyiannis P, Trygonis S et al. Modifier effect of the Glu298Asp polymorphism of endothelial nitric oxide synthase gene in autosomal-dominant polycystic kidney disease. Nephron. Clin. Pract. 2008; 110: c101-6.
15. Lee JG, Ahn C, Yoon SC et al. The Glu/Asp polymorphism of ecNOS gene and the renal progression in Korean autosomal dominant polycystic kidney disease (ADPKD) patients. Korean J. Genet. 2002; 24: 241-6.
16. Tazon-Vega B, Vilardell M, Perez-Oller L et al. Study of candidate genes affecting the progression of renal disease in autosomal dominant polycystic kidney disease type 1. Nephrol. Dial. Transplant. 2007; 22: 1567-77.
17. Ramanathan G, Periyasamy S, Lakkakula BV. NOS3 tagSNPs does not modify the association between CKD progression in ADPKD. Nephrology (Carlton) 2014; 19: 537-41.
18. Nie W, Li B, Xiu QY. The -675 4G/5G polymorphism in plasminogen activator inhibitor-1 gene is associated with risk of asthma: A meta-analysis. PLoS ONE 2012; 7: e34385.
19. Egger M, Davey Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
20. Merta M, Reiterova J, Rysava R et al. Role of endothelin and nitric oxide in the pathogenesis of arterial hypertension in autosomal dominant polycystic kidney disease. Physiol. Res. 2003; 52: 433-7.
21. Wang D, Braendstrup O, Larsen S et al. The expression and activity of renal nitric oxide synthase and circulating nitric oxide in polycystic kidney disease rats. APMIS 2004; 112: 358-68.
22. Wang D, Iversen J, Strandgaard S. Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 2000; 11: 1371-6.
23. Zintzaras E, Papathanasiou AA, Stefanidis I. Endothelial nitric oxide synthase gene polymorphisms and diabetic nephropathy: A HuGE review and meta-analysis. Genet. Med. 2009; 11: 695-706.
24. Yoshida I, Bengal R, Torres VE. Gender-dependent effect of L-NAME on polycystic kidney disease in Han:SPRD rats. Am. J. Kidney Dis. 2000; 35: 930-36.
25. Wang D, Iversen J, Wilcox CS et al. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int. 2003; 64: 1381-8.
26. Ahmed SB, Fisher ND, Hollenberg NK. Gender and the renal nitric oxide synthase system in healthy humans. Clin. J. Am. Soc. Nephrol. 2007; 2: 926-31.
27. Baylis C. Sexual dimorphism in the aging kidney: Differences in the nitric oxide system. Nat. Rev. Nephrol. 2009; 5: 384-96.